Evaluation of the safety and tolerability of exogenous ketosis induced by orally administered free beta-hydroxybutyrate in healthy adult subjects

被引:1
|
作者
Pimentel-Suarez, Lisa Isabel [1 ,2 ]
Soto-Mota, Adrian [1 ,2 ]
机构
[1] Natl Inst Med Sci & Nutr Salvador Zubiran, Metab Dis Res Unit, Mexico City, Mexico
[2] Tecnol Monterrey, Sch Med, Campus Ciudad Mexico, Ciudad De Mexico, Mexico
关键词
nutritional treatment;
D O I
10.1136/bmjnph-2023-000672
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Beta-hydroxybutyrate (D-BHB) is a metabolite with intrinsic signalling activity that has gained attention as a potentially clinically useful supplement. There are available supplements for inducing ketosis: ketone salts, ketone esters and medium-chain triglycerides. Even when all of them raise D-BHB in the blood and all are safe and well tolerated, they significantly differ in their safety profile, their palatability and their price. A fourth and potentially interesting option is to use biologically identical D-BHB, which it is already commercially available in the USA (American Ketone) and Greater China (MedPHA). However, its safety and tolerability had not yet been documented in the scientific literature. We evaluated the safety and tolerability of orally administered free D-BHB in a gender and age-balanced sample of 24 asymptomatic and overtly healthy adults. No participant showed acid-base abnormalities or electrolyte abnormalities. Secondary symptoms were reported after only 6.2% of all drink takes and none of the reports described the symptom as 'severe'. The most frequently reported secondary effects (19/720 or 2.6%) were gastrointestinal discomfort, headache (7/720 or 1%) and loss of appetite (7/720 or 1%). No correlation between weight-adjusted dose and frequency of secondary symptoms was observed. Free D-BHB was a safe and well-tolerated intervention for inducing sustained exogenous ketosis. Being bioidentical, salt-free and lacking intermediate metabolites, this form of supplementation could have a larger safety spectrum than salt or alcohol-based exogenous ketones. More research is warranted to assess its clinical efficacy in those clinical scenarios in which achieving ketosis rapidly could be beneficial.
引用
收藏
页码:122 / 126
页数:5
相关论文
共 14 条
  • [1] Ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib administered orally with multiple doses of ketoconazole to healthy adult subjects
    El Gaaloul, M.
    Abbas, R.
    Hug, B.
    Leister, C.
    Chalon, S.
    Sonnichsen, D.
    EJC SUPPLEMENTS, 2009, 7 (02): : 132 - 132
  • [2] Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects
    Clarke, Kieran
    Tchabanenko, Kirill
    Pawlosky, Robert
    Carter, Emma
    King, M. Todd
    Musa-Veloso, Kathy
    Ho, Manki
    Roberts, Ashley
    Robertson, Jeremy
    VanItallie, Theodore B.
    Veech, Richard L.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2012, 63 (03) : 401 - 408
  • [3] Orally administered TQ-A3334 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics single and multiple ascending doses in healthy Chinese subjects
    Hu, Yue
    Zhang, Hong
    Wu, Min
    Huo, Dandan
    Chen, Hong
    Li, Xiaojiao
    Xu, Zhongnan
    Ding, Yanhua
    Niu, Junqi
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E466 - E467
  • [4] EVALUATION OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ALDAFERMIN IN HEALTHY ADULT MALE JAPANESE AND NON-JAPANESE SUBJECTS
    Li, Yan
    Chan, Ming Liang
    Harr, Mihoko
    Nguyen, David
    Ling, Lei
    Willett, Michael S.
    HEPATOLOGY, 2022, 76 : S756 - S756
  • [5] Safety and tolerability of orally administered RPC1063, a novel S1P1 receptor agonist, in healthy adult volunteers
    Hartung, J.
    Peach, R.
    Boehm, M.
    Rosen, H.
    Smith, H.
    Pan, C.
    Brooks, J.
    Timony, G.
    Gujrathi, S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 186 - 186
  • [6] Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK2269557 (Nemiralisib) Administered Via Dry Powder Inhaler to Healthy Japanese Subjects
    Ino, Hiroko
    Wilson, Robert
    Terao, Takumi
    Ogura, Hirofumi
    Igarashi, Harue
    Cahn, Anthony
    Numachi, Yotaro
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (01): : 78 - 86
  • [7] EVALUATION OF THE TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORALLY ADMINISTERED DWP05195, A NEW TRPV1 ANTAGONIST IN HEALTHY ADULT MALE VOLUNTEERS.
    Lee, S.
    Jiang, F.
    Lee, J.
    Chung, J.
    Jang, I.
    Lee, H.
    Yu, K.
    Jang, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S77 - S77
  • [8] Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects
    Chakraborty, Subhra
    Harro, Clayton
    DeNearing, Barbara
    Bream, Jay
    Bauers, Nicole
    Dally, Len
    Flores, Jorge
    de Verg, Lillian Van
    Sack, David A.
    Walker, Richard
    CLINICAL AND VACCINE IMMUNOLOGY, 2016, 23 (04) : 315 - 325
  • [9] Safety and Tolerability of Orally Administered RPC1063, a Novel S1P1 Receptor Modulator, in Healthy Adult Volunteers, Results of a Phase 1 Study
    Olson, Allan
    Hartung, Jeffrey
    Timony, Gregg
    Peach, Robert
    Boehm, Marcus
    Rosen, Hugh
    Smith, Heather
    Pan, Christine
    Brooks, Jennifer
    Gujrathi, Sheila
    NEUROLOGY, 2013, 80
  • [10] A randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CBP-201 administered to healthy adult subjects
    Royal, Mike A.
    White, Jeffery
    Snyder, Ben
    Wei, Zheng
    Pan, Wubin
    Wang, Junying
    Sansone, Kenneth J.
    Yang, Xin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB159 - AB159